medigraphic.com
ISSN 2070-8718 (Print)

2015, Number 3

<< Back Next >>

Rev Cub Gen 2015; 9 (3)

Genetic and metabolic biomarkers in autism spectrum disorders

Quintana HD

Language: Spanish
References: 48
Page: 14-22
PDF size: 464.69 Kb.


ABSTRACT

Introduction: Autism spectrum disorders are complex and heterogeneous, and are caused by an interaction between genetic predisposition and environmental factors. Nowadays, the identification of the underlying bases of these disorders poses a challenge for science, in order to improve its diagnosis and treatment. Objective: To provide an update on the potential of genetic and metabolic biomarkers in the diagnosis of patients with autism spectrum disorders. Methods: A search in PubMed/MEDLINE publications of the last five years was performed, only those articles with new information on the subject, which full text was available, were included. Results: Biomedical research has uncovered several genetic and metabolic biomarkers, including epigenetic, oxidative stress and mitochondrial dysfunction, however, the diagnosis these disorders cannot be attributed to any specific marker. Conclusions: Currently there is no enough evidence to support the use of effective biomarkers for the diagnosis of autism spectrum disorders.


REFERENCES

  1. Fernández Jaén A, Cigudosa JC, Fernández Mayoralas DM, Suela J, Fernández Perrone AL, Calleja Pérez B, et al. Genética aplicada a la práctica clínica en trastornos del neurodesarrollo. Rev Neurol. 2014; 58 (Supl 1): S65-70.

  2. Goldani AA, Downs SR, Widjaja F, Lawton B, Hendren RL. Biomarkers in Autism. Front Psychiatry. 2014; 5:100.

  3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.

  4. Insel T. Director’s Blog: A New Approach to Clinical Trials [Internet]. 2014. Disponible en: http://www.nimh.nih.gov/ about/director/2014/a-new-approach-to-clinical-trials.shtml

  5. Hagerman R, Hendren R. Treatments for Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms. New York, NY: Oxford University Press; 2014.

  6. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res. 2011;1380:42.

  7. Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. Cell. 2014; 156(5):872.

  8. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010; 86: 749-64.

  9. Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med. 2013;15:399-407

  10. Lubs HA, Stevenson RE, Schwartz CE. Fragile X and X-linked intellectual disability: four decades of discovery. Am J Hum Genet. 2012;90:579-90.

  11. Ostrer H. Changing the game with whole exome sequencing. Clin Genet. 2011;80:101-3.

  12. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011;68:1095.

  13. El-Fishawy P, State MW. The genetics of autism: key issues, recent findings, and clinical implications. Psychiatr Clin North Am. 2010; 33:83.

  14. State MW, Levitt P. The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci. 2011;14:1499.

  15. Wang K, Zhang HT, Ma DQ, Bucan M, Glessner JT, Abrahams BS, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 2009;459:528.

  16. Lee TL, Raygada MJ, Rennert OM. Integrative gene network analysis provides novel regulatory relationships, genetic contributions and susceptible targets in autism spectrum disorders. Gene. 2012;496:88.

  17. Sener EF, Oztop DB, Ozkul Y. MTHFR Gene C677T Polymorphism in Autism Spectrum Disorders. Genet Res Int. 2014; 2014: 698574

  18. Schmidt RJ, Hansen RL, Hartiala J, Allayee H, Schmidt LC, Tancredi DJ, et al. Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. Epidemiology. 2011;22:476.

  19. Liu Y, Du Y, Liu W, Yang C, Wang H, Gong X. Lack of association between NLGN3, NLGN4, SHANK2 and SHANK3 gene variants and autism spectrum disorder in a Chinese population. PLoS One. 2013;8:e56639..

  20. Volaki K, Pampanos A, Kitsiou-Tzeli S, Vrettou C, Oikonomakis V, Sofocleous C, et al. Mutation screening in the Greek population and evaluation of NLGN3 and NLGN4X genes causal factors for autism. Psychiatr Genet. 2013; 23:198.

  21. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo mutations revealed by wholeexome sequencing are strongly associated with autism. Nature. 2012; 485:237.

  22. Wong CC, Meaburn EL, Ronald A, Price TS, Jeffries AR, Schalkwyk LC, et al. Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. Mol Psychiatry. 2014;19:495.

  23. Ma DK, Marchetto MC, Guo JU, Ming GL, Gage FH, Song H. Epigenetic choreographers of neurogenesis in the adult mammalian brain. Nat Neurosci. 2010; 13:1338.

  24. Peaston A, Whitelaw E. Epigenetics and phenotypic variation in mammals. Mammalian Genome. 2006 [citado 14 7 2015]; 17(5):365–374.

  25. Rodenhiser D, Mann M. Epigenetic and human disease: translating basic biology into clinical applications. CMAJ. 2006; 74(3):341–348.

  26. Gregory SG, Connelly JJ, Towers AJ, Johnson J, Biscocho D, Markunas CA, et al. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med. 2009;7:62.

  27. Na ES, Monteggia LM. The role of MeCP2 in CNS development and function. Horm Behav. 2011; 59(3):364–368.

  28. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012; 17:290.

  29. El-Ansary A, Al-Ayadhi L. Lipid mediators in plasma of autism spectrum disorders. Lipids Health Dis. 2012;11:160.

  30. Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J, et al. Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med. 2012; 16:1184.

  31. Ratajczak HV. Theoretical aspects of autism: biomarkers – a review. J Immunotoxicol. 2011;8:80.

  32. Seneff S, Lauritzen A, Davidson RM, Lentz-Marino L. Is encephalopathy a mechanism to renew sulfate in autism? Entropy. 2013; 15:372.

  33. Baribeau DA, Anagnostou E. Social communication is an emerging target for pharmacotherapy in autism spectrum disorder – a review of the literature on potential agents. J Can Acad Child Adolesc Psychiatry. 2014;23:20.

  34. Modahl C, Green L, Fein D, Morris M, Waterhouse L, Feinstein C, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry. 1998; 43:270.

  35. Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation. 2012;9:201.

  36. Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J. 2014;28(6):2398.

  37. Venkataraman A, Duncan JS, Yang J, Pelphrey K. An unbiased Bayesian approach to functional connectomics implicates social-communication networks in autism. Neuroimage Clin. 2015; 8:356–366.

  38. Challis C, Berton O. Top-down control of serotonin systems by the prefrontal cortex: a path towards restored socioemotional function in depression. ACS Chem Neurosci. 2015; 6(7): 1040–1054.

  39. Nyffeler J, Walitza S, Bobrowski E, Gundelfinger R, Grünblatt E. Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism. J Mol Psychiatry. 2014;2(1): 1.

  40. Jain SK, Micinski D. Vitamin D upregulates glutamate cysteine ligase and glutathione reductase, and GSH formation, and decreases ROS and MCP-1 and IL-8 secretion in high-glucose exposed U937 monocytes. Biochem Biophys Res Commun. 2013 [citado 24 7 2015];437:7.

  41. Frye RE, Delatorre R, Taylor H, Slattery J, Melnyk S, Chowdhury N, et al. Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Transl Psychiatry. 2013;3:e273.

  42. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med. 2012;52:2128.

  43. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80:1611–7.

  44. Gorrindo P, Lane CJ, Lee EB, McLaughlin B, Levitt P. Enrichment of elevated plasma F2t-isoprostane levels in individuals with autism who are stratified by presence of gastrointestinal dysfunction. PLoS One. 2013;8:e68444.

  45. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13:171–81.

  46. Fernández-Checa JC, Fernández A, Morales A, Mari M, Garcia-Ruiz C, Colell A. Oxidative stress and altered mitochondrial function in neurodegenerative diseases: lessons from mouse models. CNS Neurol Disord Drug Targets. 2010;9:439-54.

  47. Rose, D. Walke, J. Beddoes, D. Farrow, L. Stratified medicine in psychiatry: what service users, carers and the public think. Ment Health Today. 2014;24-7.

  48. Duval, F. Mokrani, MC. Crocq, MA. What future for neuroendocrinology in psychiatry? Psycho –neuroendocrinology.20 13;38(8):1213-9.




2020     |     www.medigraphic.com